Strassels S A, Sullivan S D
Department of Pharmacy, University of Washington, Seattle 98195, USA.
Pharmacotherapy. 1997 Jan-Feb;17(1):133-9.
We evaluated the medical and economic literature pertaining to varicella vaccine in healthy children in an effort to provide perspective for both clinicians and those responsible for making payment policies. Chickenpox is relatively mild in most immunocompetent children; however, disease-related direct and indirect medical costs have been estimated at approximately $400 million/year. A vaccine effective in preventing the disease is now available in the United States and may offset some of these expected costs. Universal vaccination for patients older than 12 months of age without history of varicella infection or other contraindication is recommended by the American Academy of Pediatrics. It is estimated that it would save $0.90/dollar spent and $5.40/dollar spent from payers' and society's perspectives, respectively. Thus varicella vaccination is cost-beneficial only when considered from a societal perspective.
我们评估了与健康儿童水痘疫苗相关的医学和经济学文献，以便为临床医生和负责制定支付政策的人员提供参考。在大多数免疫功能正常的儿童中，水痘病情相对较轻；然而，据估计，与水痘疾病相关的直接和间接医疗费用每年约为4亿美元。美国现已有一种有效预防该疾病的疫苗，它可能会抵消一些预期成本。美国儿科学会建议，对12个月以上无水痘感染史或其他禁忌证的患者进行普遍接种。据估计，从支付方和社会的角度来看，每花费1美元分别可节省0.90美元和5.40美元。因此，只有从社会角度考虑，水痘疫苗接种才具有成本效益。
